The SidebySide Partnership is a London based Enterprise Investment Scheme (EIS) Venture Capital (VC) firm. Its purpose is to finance and control the management teams of its investee companies enabling them to become a developed corporate entity. The SidebySide Partnership's focus is on fast-growing technology businesses with £1 - 10 million in revenue. It provides 100% EIS relief on investment with zero initial/ongoing fees charged to investors. The SidebySide Partnership's investment experience of 20+ corporate acquisitions totalling more than $200 million, 20+ private investments, and a rate of interest of 12x over the last 35 years has enabled it to become a dependable platform for upcoming tech businesses. It will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£1,500,000
Lightpoint Medical is a technology company that is a pioneer in developing and marketing precision-guided cancer surgery. Surgeons aren't able to see if the cancerous tissue has been removed in its entirety or not during a surgery. To better this situation, the company has developed an imaging technology based on PET radiopharmaceuticals, more precisely, Cerenkov Luminescence Imaging (CLI), which helps surgeons to detect cancer in a real-time during surgery. The company's first product has received marketing authorisation, i.e., the CE (European Conformity) Mark. A second product, a laparoscopic device for prostate cancer is in development. A non-clinical device has also been released. For its efforts, Lightpoint Medical won the 'Best in Show' Award at the 2014 MedTech Investing Europe Conference. The company aims to utilise the investment to scale its business.
days to go:
Expired
investment:
Withheld
Trustco Capital is a value-added financial intermediary that acts as a bridge between suppliers and users of capital. Through its investor network, the company supports entrepreneurs and startup enterprises with capital allowing their business to advance further. The company's partnership venture, ‘The Envestry Investment Management Programme’, allows Trustco, as a licensee, the ability to introduce its investor client network and its deals to Envestors and the other licensees leading to a combined investor network of over 6,000+ individuals. This also allows users to view 20 to 30 deals that are mostly SEIS and EIS eligible backed by the Financial Conduct Authority (FCA).
days to go:
Expired
investment:
Withheld
Run3D is a biotechnology company that has developed a 3D gait analysis system with the aim to help people identify injuries, deliver better performance, and make better running decisions. 3D gait analysis involves using infrared cameras to track positions of small reflective markers attached to a person in motion, capturing measurable data to help quantify a person's risk of injury, biomechanical efficiency, performance, footwear, and recommend proper diagnosis where necessary. The company plans to use the investment to grow its business.
days to go:
Expired
investment:
Withheld
Founded by entrepreneurs, Oliver Hutley (COO) and Rory Chichester (CEO), TECS Group is an expert provider of technology. TECS Group delivers non-discretionary critical services, such as Electrical Testing and Treatment, Gas Safety, and Fire Safety, on behalf of customers. These services are covered by strict legislation & regulation. Following a constant period of investment into developing a scalable and a solid operating platform, the TECS Group is embarking on its subsequent stage of growth. With the proceeds, the company will deliver and successfully implement its technology strategy, successfully drive for organic sales, increase the national coverage, and continue its final program.
days to go:
Expired
investment:
£96,770
FinOptix is an innovative FinTech company that solves real business problems. FinOptix’s objective is to become a significant player in a rapidly growing FinTech market by developing systems that provide financial clarity to decision-makers. FinOptix has a well-established user base, as well as a sales pipeline that covers multiple geographies and sectors. Their verification and validation procedures applied during the development process and operational trials have led to engagement with commercial partners. With the proceeds, they will design an Evaluator for the future, apply AI techniques to solve complex problems, develop their skill set and framework and hire a team of data scientists based on the assessment.
days to go:
Expired
investment:
£125,000
GymBuddy is an online platform that enables consumers to find, book, and attend a gym location, services, or products offered and operated by fitness studios, gyms, trainers, venues, or other third parties. Users can easily, through filtered searches on the app, view descriptions, and contact information of specialists within the fitness industry such as personal trainers, nutritionists, and physiotherapists. The UK fitness industry alone is currently worth over £5 billion. Based on recent statistics, the average gym membership in the UK costs members £40 a month, which often ties them into lengthy contracts. The GymBuddy app will enter the Health & Fitness club sector as a multi-gym membership feature that gives users access to gyms and various fitness plans, without the need for bricks-and-mortar locations under its brand. The company is seeking an investment of £400,000 to expand its brand identity and bring more users to its ecosystem to generate profits.
days to go:
Expired
investment:
Withheld
Butterwire is a professional research and portfolio analyst platform designed for high conviction low turnover active equity managers. Butterwire's AI web application was launched in June 2018 and is used by all active equity investors aiming to generate higher returns, with faster stock selection, longer investment horizons, lower portfolio risk, and less trading. The application assists active investors with their top 3 challenges: find opportunities, minimise risk, and keep aware. It is built by and for professionals but is accessible to individual investors, too. The company will utilize 10% of the proceeds to operations, 25% to development, 15% to research, 40% to business development, and 10% to administration.
days to go:
Expired
investment:
Withheld
Antev Limited (Antev) is a clinical-stage biopharmaceutical firm which focuses on the evolution of a drug used for prostate cancer, Teverelix TFA. The company is working on growing its copyright protection and is currently developing phase IIb clinical plans for prostate cancer. Antev is a pre-revenue company that aims at increasing its shareholder value by progressing the development of teverelix TFA towards registration whose approval is anticipated from 2023 onwards. The proceeds will be used for production, IP development, working capital and to develop a phase IIb repeat dosing clinical trial in prostate cancer.
days to go:
Expired
investment:
Withheld
epaysecure is a secure payment system, which offers comprehensive payment and benefit options, and allows all the services the consumer demands to be offered in one card and e-account. The prepaid business purchasing in European markets is estimated to be $700 million. The company operates in an e-banking and financial services marketing sector that helps clients by identifying new markets and bringing in new ideas to develop them through reloadable products and e-Wallet platform. The funds will be used for staffing, set up costs, other overheads including property marketing and general office costs.
days to go:
Expired
investment:
£168,340
